Trial · NCT00699335
Matrifen® for Therapy of Severe Chronic Pain®
NCT00699335, Completed, Nycomed; results first posted 2010-08-12
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Matrifen® for Therapy of Severe Chronic Pain®. Trials, record NCT00699335. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00699335
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Matrifen® for Therapy of Severe Chronic Pain®
- NCT number
- NCT00699335
- Status
- Completed
- Enrollment
- 5,308 participants, actual
- Lead sponsor
- Nycomed
- Conditions
- Severe Chronic Pain
- Interventions
- Fentanyl
- First posted
- 2008-06-18
- Last updated
- 2012-05-08
- Results first posted
- 2010-08-12
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Patient's Assessment of Pain Severity Score | Before and after therapy with Matrifen® (4 weeks) | Assessment on a Visual Analogue Scale from 0=No pain to 10=Most severe pain |
| Primary | Physician's Final Assessment of the Efficacy of Therapy With Matrifen® | After 4 week therapy with Matrifen® | Assessment on a scale: Excellent, good, satisfactory, dissatisfactory |
| Primary | EQ-5D (Optional): Domain Mobility | Before and after therapy with Matrifen® (4 weeks) | This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no problems in walking around 2. I have some problems in walking around 3. I am confined to bed |
| Primary | EQ-5D (Optional): Domain Self Care | Before and after therapy with Matrifen® (4 weeks) | This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no problems with self-care 2. I have some problems washing or dressing myself 3. I am unable to wash or dress myself |
| Primary | EQ-5D (Optional): Domain Usual Activities | Before and after therapy with Matrifen® (4 weeks) | This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no problems with performing my usual activities 2. I have some problems with performing my usual activities 3. I am unable to perform my usual activities |
| Primary | EQ-5D (Optional): Pain / Discomfort | Before and after therapy with Matrifen® (4 weeks) | This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I have no pain or discomfort 2. I have moderate pain or discomfort 3. I have extreme pain or discomfort |
| Primary | EQ-5D (Optional): Domain Anxiety / Depression | Before and after therapy with Matrifen® (4 weeks) | This outcome measure to assess patients quality of life is based on an optional standardised patient questionnaire (EQ-5D). Questions on a scale from 1-3 at initial and final visit: 1. I am not anxious or depressed 2. I am moderately anxious or depressed 3. I am extremely anxious or depressed |
| Primary | EQ-5D (Optional): European Index Score | Before and after therapy with Matrifen® (4 weeks) | Index derived from the five EQ-5D-items (= mobility, self care, usual activities, pain/discomfort, anxiety/depression) resulting in a value from -1= very ill to 1=full health |
| Primary | EQ-5D (Optional): Visual Analogue Scale | Before and after therapy with Matrifen® (4 weeks) | Visual Analogue Scale (VAS) from 0 =worst imaginable health status, 100 =best imaginable health status |
| Secondary | Physician's Assessment of the Skin Tolerability of the Fentanyl-patches | After 4 week therapy with Matrifen® | Assessment on a scale: Excellent, good, satisfactory, dissatisfactory |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Patient's Assessment of Pain Severity Score | Before and after therapy with Matrifen® (4 weeks) | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | Units on a scale | MEAN |
| PRIMARY | Physician's Final Assessment of the Efficacy of Therapy With Matrifen® | After 4 week therapy with Matrifen® | All patients included and treated, intention to treat, missing values not imputed | Participants | NUMBER |
| PRIMARY | EQ-5D (Optional): Domain Mobility | Before and after therapy with Matrifen® (4 weeks) | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | Participants | NUMBER |
| PRIMARY | EQ-5D (Optional): Domain Mobility | Before and after therapy with Matrifen® (4 weeks) | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | Units on a scale | MEAN |
| PRIMARY | EQ-5D (Optional): Domain Self Care | Before and after therapy with Matrifen® (4 weeks) | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | Participants | NUMBER |
| PRIMARY | EQ-5D (Optional): Domain Self Care | Before and after therapy with Matrifen® (4 weeks) | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | Units on a scale | MEAN |
| PRIMARY | EQ-5D (Optional): Domain Usual Activities | Before and after therapy with Matrifen® (4 weeks) | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | Participants | NUMBER |
| PRIMARY | EQ-5D (Optional): Domain Usual Activities | Before and after therapy with Matrifen® (4 weeks) | Units on a scale | MEAN | |
| PRIMARY | EQ-5D (Optional): Pain / Discomfort | Before and after therapy with Matrifen® (4 weeks) | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | Participants | NUMBER |
| PRIMARY | EQ-5D (Optional): Pain / Discomfort | Before and after therapy with Matrifen® (4 weeks) | Patients included and treated with valid data at first and last visit (without imputation of missing values), intention to treat | Units on a scale | MEAN |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 outcomesResults by group71
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Patient's Assessment of Pain Severity Score | Matrifen® | Start of therapy | 7.12 | Standard Deviation 1.52 | Units on a scale |
| Patient's Assessment of Pain Severity Score | Matrifen® | End of study | 3.32 | Standard Deviation 1.66 | Units on a scale |
| Physician's Final Assessment of the Efficacy of Therapy With Matrifen® | Matrifen® | Excellent | 2530 | Participants | |
| Physician's Final Assessment of the Efficacy of Therapy With Matrifen® | Matrifen® | Good | 2273 | Participants | |
| Physician's Final Assessment of the Efficacy of Therapy With Matrifen® | Matrifen® | Satisfactory | 365 | Participants | |
| Physician's Final Assessment of the Efficacy of Therapy With Matrifen® | Matrifen® | Dissatisfactory | 73 | Participants | |
| Physician's Final Assessment of the Efficacy of Therapy With Matrifen® | Matrifen® | Missing data | 67 | Participants | |
| EQ-5D (Optional): Domain Mobility | Matrifen® / Initial Visit | I have no problems in walking around | 284 | Participants | |
| EQ-5D (Optional): Domain Mobility | Matrifen® / Final Visit | I have no problems in walking around | 1294 | Participants | |
| EQ-5D (Optional): Domain Mobility | Matrifen® / Initial Visit | I have some problems in walking around | 2779 | Participants |
1 to 10 of 71Source ClinicalTrials.gov
See all 71 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Matrifen® | 5,308 | |
| Overall Study | COMPLETED | Matrifen® | 5,080 | |
| Overall Study | NOT COMPLETED | Matrifen® | 228 |
Source ClinicalTrials.gov
Adverse events19
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Cardiac failure | Cardiac disorders | Matrifen® | 1 | 5,308 | 1 |
| serious | Cardiovascular disorder | Cardiac disorders | Matrifen® | 1 | 5,308 | 1 |
| serious | Dizziness | Nervous system disorders | Matrifen® | 1 | 5,308 | 1 |
| serious | Nausea | Gastrointestinal disorders | Matrifen® | 2 | 5,308 | 2 |
| serious | Constipation | Gastrointestinal disorders | Matrifen® | 1 | 5,308 | 1 |
| serious | Death | General disorders | Matrifen® | 49 | 5,308 | 49 |
| serious | General physical health deterioration | General disorders | Matrifen® | 1 | 5,308 | 1 |
| serious | Metastases to liver | Hepatobiliary disorders | Matrifen® | 1 | 5,308 | 1 |
| serious | Sepsis | Infections and infestations | Matrifen® | 1 | 5,308 | 1 |
| serious | Pelvic fracture | Injury, poisoning and procedural complications | Matrifen® | 1 | 5,308 | 1 |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Matrifen® | ||
| Total, other adverse events | Matrifen® | 0 | 5,308 |
| Total, serious adverse events | Matrifen® | 80 | 5,308 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00699335
GET https://conductscience.org/api/trials/v1/NCT00699335/results?page=2